Cytokinetics CEO Sells Over $480K in Shares

Insider sales raise questions about commercial launch of new heart drug

Mar. 11, 2026 at 11:39am

Got story updates? Submit your updates here. ›

Cytokinetics CEO Robert Blum sold 7,931 shares of the company's stock for over $480,000, raising questions about the commercial launch of the company's new heart drug. The sale comes as Cytokinetics shifts from development to commercialization, a high-stakes phase that could significantly expand revenue if the drug's uptake meets expectations.

Why it matters

Insider sales can sometimes be interpreted negatively by investors, even when the executives still maintain substantial ownership stakes. In this case, the CEO's sale, along with those of other executives, may raise concerns about the commercial progress of Cytokinetics' new heart drug, which is crucial to the company's future growth.

The details

In a regulatory filing, Cytokinetics CEO Robert Blum disclosed the sale of 7,931 shares at an average price of $60.72, for a total transaction of $481,570. Two other executives, EVP Fady I. Malik and EVP Andrew Callos, also sold shares around the same time. While the executives still hold significant positions, such insider sales can be viewed as profit-taking after the drug's launch, even if the overall holdings have only been reduced by low single-digit percentages.

  • On March 9, 2026, CEO Robert Blum sold 7,931 shares.

The players

Robert Blum

CEO of Cytokinetics, Incorporated, a biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Fady I. Malik

Executive Vice President of Cytokinetics, Incorporated.

Andrew Callos

Executive Vice President of Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The insider sales by Cytokinetics' executives raise questions about the commercial progress of the company's new heart drug, which is crucial to its future growth. While the executives still maintain substantial ownership stakes, such sales can be viewed negatively by some investors, even if the overall holdings have only been reduced by low single-digit percentages.